A new trial found a reduction in the thickness of artery walls in patients given Abbott...

|About: Abbott Laboratories (ABT)|By:, SA News Editor

A new trial found a reduction in the thickness of artery walls in patients given Abbott Laboratories' (ABT) Niaspan, while those on Merck's (MRK) Zetia had no change. The results, reported yesterday at a American Heart Association meeting, could pump up sales for Abbott’s drug, though some doctors have questioned the validity of the study.